NASDAQ:CMRX Chimerix - CMRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.26 +0.05 (+4.13%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.22▼$1.2950-Day Range$1.19▼$1.8452-Week Range$1.18▼$5.39Volume546,246 shsAverage Volume853,634 shsMarket Capitalization$111.22 millionP/E Ratio0.64Dividend YieldN/APrice Target$8.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Chimerix MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside574.6% Upside$8.50 Price TargetShort InterestBearish4.42% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment0.45Based on 5 Articles This WeekInsider TradingAcquiring Shares$24,200 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.85) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.60 out of 5 starsMedical Sector105th out of 1,004 stocksPharmaceutical Preparations Industry39th out of 489 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Chimerix has a forecasted upside of 574.6% from its current price of $1.26.Amount of Analyst CoverageChimerix has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.42% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Chimerix has recently increased by 17.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 1.9 News and Social Media Coverage News SentimentChimerix has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Chimerix this week, compared to 3 articles on an average week.Search InterestOnly 22 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Chimerix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have bought 325.68% more of their company's stock than they have sold. Specifically, they have bought $24,200.00 in company stock and sold $5,685.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Chimerix is held by insiders.Percentage Held by Institutions58.03% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to grow in the coming year, from ($0.85) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is 0.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is 0.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 79.52.Price to Book Value per Share RatioChimerix has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Chimerix (NASDAQ:CMRX) StockChimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.Read More Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Stock News HeadlinesMarch 31, 2023 | americanbankingnews.comFred A. Middleton Acquires 20,000 Shares of Chimerix, Inc. (NASDAQ:CMRX) StockMarch 6, 2023 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q4 2022 Earnings Call TranscriptApril 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...March 3, 2023 | msn.comChimerix's Earnings OutlookMarch 3, 2023 | markets.businessinsider.comJonesTrading Keeps Their Buy Rating on Chimerix (CMRX)March 2, 2023 | finance.yahoo.comChimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational UpdateFebruary 28, 2023 | finance.yahoo.comChimerix to Present at Cowen and Company 43rd Annual Health Care ConferenceFebruary 23, 2023 | finance.yahoo.comChimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023April 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...February 17, 2023 | finance.yahoo.comWith 53% ownership of the shares, Chimerix, Inc. (NASDAQ:CMRX) is heavily dominated by institutional ownersJanuary 5, 2023 | finance.yahoo.comChimerix to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2023 | thestreet.comWhy Chimerix (CMRX) Stock Is Tanking TodayNovember 29, 2022 | finance.yahoo.comChimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?November 14, 2022 | bizjournals.comHedge fund urges Durham drugmaker Chimerix to liquidateNovember 10, 2022 | finance.yahoo.comRubric Capital Management Sends Letter to Chimerix Board of DirectorsNovember 10, 2022 | finance.yahoo.comChimerix Responds to Rubric Capital ManagementNovember 4, 2022 | finance.yahoo.comBuy 3 of the Best Stocks by Using Net Income RatioNovember 3, 2022 | finance.yahoo.comChimerix (CMRX) Beats Q3 Earnings EstimatesNovember 3, 2022 | finance.yahoo.comChimerix Reports Third Quarter 2022 Financial Results and Provides Operational UpdateOctober 27, 2022 | finance.yahoo.comChimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022October 11, 2022 | nasdaq.comWill UnitedHealth Group (UNH) Beat Q3 Earnings Estimates? - NasdaqOctober 5, 2022 | proactiveinvestors.comKazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia - Proactive Investors USAOctober 5, 2022 | uk.investing.com$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying By Benzinga - Investing.com UKSeptember 28, 2022 | bizjournals.comDurham pharma nets $238M for smallpox drug with more payouts lined up - The Business JournalsSeptember 27, 2022 | finance.yahoo.comEmergent BioSolutions closes acquisition of smallpox drug from ChimerixSeptember 26, 2022 | globenewswire.comEmergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages - GlobeNewswireSeptember 26, 2022 | globenewswire.comChimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Company Calendar Last Earnings3/02/2023Today4/01/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees87Year Founded2000Price Target and Rating Average Stock Price Forecast$8.50 High Stock Price Forecast$11.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+574.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.96 Trailing P/E Ratio0.64 Forward P/E RatioN/A P/E GrowthN/ANet Income$172.17 million Net Margins509.01% Pretax Margin509.11% Return on Equity113.54% Return on Assets99.47% Debt Debt-to-Equity RatioN/A Current Ratio11.18 Quick Ratio11.18 Sales & Book Value Annual Sales$33.82 million Price / Sales3.29 Cash Flow$1.97 per share Price / Cash Flow0.64 Book Value$2.92 per share Price / Book0.43Miscellaneous Outstanding Shares88,270,000Free Float81,036,000Market Cap$111.22 million OptionableOptionable Beta1.18 Social Links Key ExecutivesMichael A. ShermanPresident, Chief Executive Officer & DirectorMichael T. AndrioleChief Financial & Business OfficerRoy W. WareChief Technology & Manufacturing OfficerCaryn BarnettVice President-Clinical OperationsAllen MelemedChief Medical OfficerKey CompetitorsRVL PharmaceuticalsNASDAQ:RVLPOpiant PharmaceuticalsNASDAQ:OPNTViveon Health AcquisitionNYSE:VHAQBriaCell TherapeuticsNASDAQ:BCTXTrevi TherapeuticsNASDAQ:TRVIView All CompetitorsInsiders & InstitutionsFred A MiddletonBought 20,000 shares on 3/28/2023Total: $24,200.00 ($1.21/share)MetLife Investment Management LLCBought 44,657 shares on 3/23/2023Ownership: 0.051%Alliancebernstein L.P.Bought 11,200 shares on 2/16/2023Ownership: 0.176%State of WyomingBought 71,611 shares on 2/16/2023Ownership: 0.081%Jane Street Group LLCSold 32,751 shares on 2/15/2023Ownership: 0.106%View All Insider TransactionsView All Institutional Transactions CMRX Stock - Frequently Asked Questions Should I buy or sell Chimerix stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares. View CMRX analyst ratings or view top-rated stocks. What is Chimerix's stock price forecast for 2023? 3 Wall Street research analysts have issued 12 month price targets for Chimerix's stock. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they expect the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 574.6% from the stock's current price. View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts. How have CMRX shares performed in 2023? Chimerix's stock was trading at $1.86 at the beginning of 2023. Since then, CMRX stock has decreased by 32.3% and is now trading at $1.26. View the best growth stocks for 2023 here. Are investors shorting Chimerix? Chimerix saw a increase in short interest in March. As of March 15th, there was short interest totaling 3,290,000 shares, an increase of 17.5% from the February 28th total of 2,800,000 shares. Based on an average daily volume of 745,700 shares, the short-interest ratio is currently 4.4 days. Currently, 4.4% of the company's stock are sold short. View Chimerix's Short Interest. When is Chimerix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our CMRX earnings forecast. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) issued its earnings results on Thursday, March, 2nd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.24). The biopharmaceutical company earned $0.81 million during the quarter, compared to analysts' expectations of $2.60 million. Chimerix had a trailing twelve-month return on equity of 113.54% and a net margin of 509.01%. During the same period in the previous year, the firm earned ($0.45) earnings per share. What ETFs hold Chimerix's stock? ETFs with the largest weight of Chimerix (NASDAQ:CMRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM). What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD). What is Chimerix's stock symbol? Chimerix trades on the NASDAQ under the ticker symbol "CMRX." How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Chimerix's stock price today? One share of CMRX stock can currently be purchased for approximately $1.26. How much money does Chimerix make? Chimerix (NASDAQ:CMRX) has a market capitalization of $111.22 million and generates $33.82 million in revenue each year. The biopharmaceutical company earns $172.17 million in net income (profit) each year or $1.96 on an earnings per share basis. How can I contact Chimerix? Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146. This page (NASDAQ:CMRX) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.